Abstract
This is a single-center review of retrospectively collected computerized data and medical records of all the patients who have undergone high dose chemotherapy and ASCT for transformed lymphoma from 1999–2014. The primary endpoint of the study was overall survival (OS) and secondary endpoint was progression free survival (PFS). A total of 27 patients with histological transformation were identified. This included transformation from follicular lymphoma Grade 1–3A and non-follicular indolent lymphoma, synchronous and asynchronous presentation. All transformed to diffuse large B cell lymphoma. 33% were chemotherapy naive prior to transformation. Median follow up was 47 months. For the entire cohort OS at 3 years was 73% and PFS = 82%. The treatment has low risk for nonrelapse mortality providing durable remission.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
